论文部分内容阅读
目的探讨应用改善病情抗风湿药物联合治疗类风湿关节炎的临床疗效。方法选取本院2010年7月~2012年6月收治的136例类风湿关节炎患者为研究对象,将其随机分为A组与B组,A组68例患者应用甲氨蝶呤、来氟米特及白芍总甙胶囊进行治疗,B组68例患者应用甲氨蝶呤、柳氮磺胺吡啶及羟氯喹联合改善病情抗风湿药物联合药治疗,比较两组患者临床效果及不良反应。结果治疗1个月、3个月后两组各项指标均较治疗前有明显改善,相比差异具有统计学意义(P<0.05);治疗1个月后A组患者疗效明显优于B组,相比差异具有统计学意义(P<0.05),但治疗3个月后A组与B组患者疗效相比,差异无统计学意义(P>0.05),不良反应发生率相比,差异也无统计学意义(P>0.05)。结论两组联合用药方案均具有安全有效的特点,但应用甲氨蝶呤、来氟米特及白芍总甙胶囊物进行治疗起效较快。
Objective To investigate the clinical efficacy of rheumatoid arthritis combined with anti-rheumatic drugs in the treatment of rheumatoid arthritis. Methods A total of 136 patients with rheumatoid arthritis who were treated in our hospital from July 2010 to June 2012 were selected and randomly divided into group A and group B. 68 patients in group A received methotrexate, Mitt and paeoniflorin capsules for treatment, B group of 68 patients with methotrexate, sulfasalazine and hydroxychloroquine combined with anti-rheumatic drugs to improve the combination therapy, the clinical effects and adverse reactions in both groups were compared. Results After treatment for 1 month and 3 months, the indexes in both groups were significantly improved compared with those before treatment (P <0.05), and the therapeutic effect in group A was significantly better than that in group B after 1 month of treatment , Compared with the difference was statistically significant (P <0.05), but after 3 months of treatment, the efficacy of group A and B was no significant difference (P> 0.05), the incidence of adverse reactions compared to the difference No statistical significance (P> 0.05). Conclusions The combination regimen of the two groups is safe and effective. However, methotrexate, leflunomide and total glucosides of paeony root are effective in the treatment.